HBK Investments’s Myriad Genetics MYGN Stock Holding History

HBK Investments’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-31,751	Closed	-$653K	–	824
2016 Q3	$653K	Sell	31,751 -18,349	-37%	-$465K	0.01%	598
2016 Q2	$1.53M	Buy	+50,100	New	+$1.74M	0.01%	475
2013 Q3	–	Sell	-18,300	Closed	-$492K	–	927
2013 Q2	$492K	Buy	+18,300	New	+$530K	0.01%	573

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HBK Investments's MYGN Position: Q4 2016 in Review

HBK Investments sold out of Myriad Genetics (MYGN) in Q4 2016, closing a stake of 31,751 shares — an estimated $653K sold.

HBK Investments first reported a position in MYGN in Q2 2013 and held it in 3 quarters. The position peaked at $1.53M in Q2 2016. 223 funds tracked by Wall St. Rank hold MYGN as of Q4 2016.

HBK Investments reported no remaining Myriad Genetics position as of Q4 2016 after selling out during the quarter.
HBK Investments sold 31,751 Myriad Genetics shares in Q4 2016, an estimated $653K.
HBK Investments first reported a position in Myriad Genetics in Q2 2013 and held it in 3 quarters.
HBK Investments's Myriad Genetics position peaked at $1.53M in Q2 2016.
223 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2016.

Based on HBK Investments's 13F filing for Q4 2016, filed 14 Feb 2017.